# Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma

> **NCT06904170** · PHASE2,PHASE3 · RECRUITING · sponsor: **UNICANCER** · enrollment: 196 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Durvalumab Plus Tremelimumab
- **DRUG:** HAIC (GEMOX)

## Key facts

- **NCT ID:** NCT06904170
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-14
- **Primary completion:** 2029-09-14
- **Final completion:** 2030-09
- **Target enrollment:** 196 (ESTIMATED)
- **Last updated:** 2026-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06904170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06904170, "Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06904170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*